Goldman Sachs’s Immunovant IMVT Stock Holding History
Bought
Maintained
Sold
Other funds holding IMVT
Goldman Sachs's IMVT Position: Q3 2026 in Review
Goldman Sachs reduced its Immunovant (IMVT) stake by 8.5% in Q3 2026, selling an estimated $5.87M and leaving 1,602,164 shares worth $54.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1645.
Goldman Sachs first reported a position in IMVT in Q1 2020 and has held it in 27 quarters since. The position peaked at $67.5M in Q2 2026. 229 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.
- Goldman Sachs held 1,602,164 shares of Immunovant worth $54.1M as of Q3 2026.
- Goldman Sachs sold 149,019 Immunovant shares in Q3 2026, an estimated $5.87M.
- Immunovant made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #1645 holding.
- Goldman Sachs first reported a position in Immunovant in Q1 2020 and has held it in 27 quarters since.
- Goldman Sachs's Immunovant position peaked at $67.5M in Q2 2026.
- 229 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.
Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.